IDNA - ARKG: More Than Just Genomes

• COVID-19 has only revealed a small glimpse of the possibilities offered by genomics, a field which is leading us towards predictive and personalized health care.
• However, ARKG goes beyond just genomic sequencing and editing.
• Despite suffering from more short-term volatility when compared to a peer, the ETF has still managed to deliver a better one-year performance.
• Still, the main question remains whether the ETF can climb back to the $110 level and higher.
• The answer is yes, as the ingredients for an upside are present and the tide seems to be turning in the growth-value debate.

For further details see: